Does Zepbound Help with Diabetes? FDA Approval, A1c Data, and the Weight-First vs Glucose-First Question

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) lowers A1c by an average of 2.1% in type 2 diabetes patients but is FDA-approved only for weight loss, not diabetes treatment
• The same molecule is sold as Mounjaro for diabetes and Zepbound for obesity, with identical mechanisms but different approved indications
• Providers prescribe Zepbound off-label for patients with both obesity and type 2 diabetes when weight loss is the primary goal and glucose control is a secondary benefit
• Tirzepatide's dual GLP-1/GIP mechanism produces stronger A1c reduction than semaglutide (Ozempic), averaging 0.5% to 0.9% better glucose control at comparable doses

Direct answer (40-60 words)

Yes, Zepbound helps with diabetes by lowering blood glucose and A1c levels through the same tirzepatide molecule that Mounjaro uses. However, Zepbound is FDA-approved only for weight loss in adults with obesity, not for diabetes treatment. Providers prescribe it off-label when weight loss is the primary goal and diabetes improvement is a welcome secondary outcome.

Table of contents

1. The regulatory distinction: why the same drug has two names
2. The clinical data: how much tirzepatide lowers A1c
3. The mechanism: why a weight-loss drug controls blood sugar
4. When providers prescribe Zepbound for patients with diabetes
5. The weight-first vs glucose-first treatment philosophy
6. Comparing tirzepatide to semaglutide for diabetes outcomes
7. What most articles get wrong about "off-label" diabetes use
8. The insulin question: can Zepbound replace basal insulin?
9. Hypoglycemia risk: when blood sugar drops too low
10. The decision framework: Mounjaro vs Zepbound for patients with both conditions
11. FormBlends clinical pattern: what we see in dual-diagnosis patients
12. FAQ
13. Sources

The regulatory distinction: why the same drug has two names

Zepbound and Mounjaro contain identical active ingredients: tirzepatide, a dual GLP-1 and GIP receptor agonist. The molecule is the same. The mechanism is the same. The side effect profile is the same. The only difference is the FDA-approved indication.

Mounjaro received FDA approval in May 2022 for type 2 diabetes management in adults. The approval was based on the SURPASS clinical trial program, which enrolled 6,000+ patients with type 2 diabetes and measured A1c reduction as the primary endpoint.

Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approval was based on the SURMOUNT clinical trial program, which enrolled 5,000+ patients without diabetes and measured weight loss as the primary endpoint.

This dual-branding strategy is common in metabolic medicine. The same molecule serves two indications, and the manufacturer markets each version to the appropriate patient population. Liraglutide follows the same pattern: Victoza for diabetes, Saxenda for weight loss. Semaglutide: Ozempic for diabetes, Wegovy for weight loss.

The practical implication: if you have type 2 diabetes and obesity, your provider can prescribe either Mounjaro or Zepbound. Insurance coverage often determines which one you receive. Mounjaro is more likely to be covered if you have a diabetes diagnosis. Zepbound is more likely to be covered if your primary diagnosis is obesity, even if you also have diabetes.

Compounded tirzepatide, which FormBlends provides access to, doesn't carry either brand name and isn't FDA-approved for any indication. Providers prescribe it off-label for both weight loss and diabetes management based on the published clinical evidence for the tirzepatide molecule.

The clinical data: how much tirzepatide lowers A1c

The SURPASS trials measured A1c reduction in patients with type 2 diabetes. The results across five trials:

Trial	Comparison	Baseline A1c	Tirzepatide dose	A1c reduction at 40 weeks	Patients achieving A1c <7%
SURPASS-1	Tirzepatide vs placebo	7.9%	15 mg	-2.1%	87%
SURPASS-1	Placebo	7.9%	N/A	-0.1%	20%
SURPASS-2	Tirzepatide vs semaglutide 1 mg	8.3%	15 mg	-2.5%	86%
SURPASS-2	Semaglutide 1 mg	8.3%	N/A	-1.9%	79%
SURPASS-3	Tirzepatide vs insulin degludec	8.2%	15 mg	-2.4%	93%
SURPASS-3	Insulin degludec (titrated)	8.2%	N/A	-1.4%	61%
SURPASS-4	Tirzepatide vs insulin glargine	8.5%	15 mg	-2.3%	82%
SURPASS-4	Insulin glargine (titrated)	8.5%	N/A	-1.1%	58%
SURPASS-5	Tirzepatide added to insulin glargine	8.3%	15 mg	-2.1%	80%

The pattern is consistent: tirzepatide at the 15 mg maintenance dose lowers A1c by 2.1% to 2.5% from baseline. About 8 in 10 patients reach the American Diabetes Association target of A1c below 7%. A meaningful subset (30% to 40% depending on baseline) reaches A1c below 5.7%, which is the non-diabetic range.

The dose-response relationship is clear:

• 5 mg: average A1c reduction of 1.9%
• 10 mg: average A1c reduction of 2.2%
• 15 mg: average A1c reduction of 2.4%

Most of the glucose-lowering effect appears by the 10 mg dose. The jump from 10 mg to 15 mg adds modest additional A1c benefit but substantially more weight loss.

For context, metformin (the first-line diabetes medication) lowers A1c by about 1.0% to 1.5%. SGLT2 inhibitors lower A1c by 0.5% to 1.0%. Basal insulin lowers A1c by 1.5% to 2.0% when titrated aggressively. Tirzepatide sits at the top of the non-insulin medication class for glucose control.

The mechanism: why a weight-loss drug controls blood sugar

Tirzepatide activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are incretin hormones, meaning they're released by the gut in response to food and signal the pancreas to release insulin.

The GLP-1 component does four things that lower blood glucose:

1. Stimulates insulin secretion in a glucose-dependent manner. When blood sugar is high, GLP-1 tells beta cells in the pancreas to release more insulin. When blood sugar is normal or low, the signal stops, which prevents hypoglycemia.
2. Suppresses glucagon secretion. Glucagon is the hormone that tells the liver to release stored glucose. Less glucagon means less glucose dumped into the bloodstream between meals.
3. Slows gastric emptying. Food leaves the stomach more slowly, which spreads the glucose absorption curve over a longer time and prevents post-meal spikes.
4. Reduces appetite and food intake. Less food consumed means fewer glucose and calorie loads to manage.

The GIP component adds:

1. Additional insulin secretion through a separate receptor pathway, creating a synergistic effect with GLP-1.
2. Improved insulin sensitivity in muscle and fat tissue, meaning the insulin that's released works more effectively.
3. Reduced inflammation in adipose tissue, which indirectly improves metabolic function.

The dual-agonist design is why tirzepatide outperforms semaglutide (a GLP-1-only agonist) in head-to-head trials. The GIP component adds roughly 0.5% to 0.9% additional A1c reduction and 2 to 4 kg additional weight loss compared to semaglutide at equivalent GLP-1 receptor activation.

The weight loss itself contributes to glucose control. Every 10 kg of weight lost typically reduces A1c by 0.3% to 0.5% in patients with type 2 diabetes, independent of medication effects. Tirzepatide patients lose an average of 15 to 21 kg over 72 weeks, which accounts for roughly 0.5% to 1.0% of the total A1c reduction. The rest comes from direct pharmacologic effects on insulin, glucagon, and gastric emptying.

When providers prescribe Zepbound for patients with diabetes

The clinical scenario where Zepbound makes sense for a patient with diabetes:

• Primary goal is weight loss. The patient has obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications, and weight reduction is the treatment priority.
• Diabetes is well-controlled or mild. A1c is between 6.5% and 8.0%, and the patient isn't on insulin or complex multi-drug regimens.
• Insurance covers Zepbound but not Mounjaro. Some plans have better formulary placement for weight-loss indications than diabetes indications.
• The provider is taking a weight-first treatment approach (see next section).

The clinical scenario where Mounjaro makes more sense:

• Primary goal is glucose control. A1c is above 8.5%, and the patient needs aggressive diabetes management.
• Weight loss is secondary. The patient may have obesity, but the immediate clinical risk is hyperglycemia and diabetes complications.
• Insurance covers Mounjaro. Most diabetes-focused plans cover Mounjaro with prior authorization.
• The patient is already on basal insulin and needs additional glucose control without adding more insulin doses.

In practice, many providers prescribe whichever version insurance will cover, because the clinical outcomes are identical. The "indication" distinction matters to the FDA and insurance companies but not to the patient's metabolism.

Compounded tirzepatide sidesteps the indication question entirely. Providers prescribe it for weight loss, diabetes, or both, based on clinical judgment rather than FDA labeling.

The weight-first vs glucose-first treatment philosophy

The traditional diabetes treatment paradigm is glucose-first: measure A1c, prescribe medications to lower A1c, escalate doses and add drugs until A1c reaches target. Weight is a secondary consideration.

The weight-first paradigm flips the priority: treat obesity as the root cause of type 2 diabetes, use weight loss as the primary intervention, and measure glucose control as an outcome of successful weight reduction.

The weight-first approach is supported by remission data. The DiRECT trial (Lean et al., Lancet, 2018) showed that 46% of patients with type 2 diabetes who lost 15 kg or more through diet achieved remission (A1c below 6.5% without medication) at 12 months. The durability wasn't perfect, but the principle held: enough weight loss can reverse type 2 diabetes in a meaningful subset of patients.

Tirzepatide produces weight loss in the range where remission becomes possible. In the SURMOUNT-1 trial (patients without diabetes), the average weight loss at 72 weeks was 21 kg at the 15 mg dose. In the SURPASS trials (patients with diabetes), the average weight loss was 11 to 13 kg, slightly lower because diabetes itself makes weight loss harder.

The weight-first philosophy says: prescribe Zepbound (or compounded tirzepatide) for obesity, monitor glucose as a secondary outcome, and celebrate if the patient's A1c drops below 6.5% and they can stop metformin. The glucose-first philosophy says: prescribe Mounjaro for diabetes, monitor A1c as the primary outcome, and celebrate if the patient also loses weight.

Both approaches use the same drug. The difference is framing and which outcome the provider prioritizes in shared decision-making with the patient.

FormBlends providers tend toward the weight-first approach because our patient population is seeking weight loss as the primary goal. If diabetes improves, that's a documented benefit, not the reason they started treatment.

Comparing tirzepatide to semaglutide for diabetes outcomes

Semaglutide (Ozempic for diabetes, Wegovy for weight loss) is the most-prescribed GLP-1 agonist. How does tirzepatide compare?

The head-to-head data comes from SURPASS-2, which directly compared tirzepatide 15 mg to semaglutide 1 mg (the standard Ozempic dose for diabetes):

Outcome	Tirzepatide 15 mg	Semaglutide 1 mg	Difference
A1c reduction at 40 weeks	-2.5%	-1.9%	-0.6% favoring tirzepatide
Patients reaching A1c <7%	86%	79%	+7% favoring tirzepatide
Weight loss at 40 weeks	-11.2 kg	-5.7 kg	-5.5 kg favoring tirzepatide
Nausea rate	22%	18%	+4% (not statistically significant)
Discontinuation due to GI side effects	6.2%	4.1%	+2.1%

Tirzepatide wins on both A1c reduction and weight loss. The cost is modestly higher nausea rates, though the difference is smaller than expected given the dual-agonist mechanism.

The comparison to semaglutide 2.4 mg (the Wegovy dose) is less direct because no head-to-head trial exists. Indirect comparison via network meta-analysis (Urva et al., Diabetes Obesity and Metabolism, 2022) suggests tirzepatide 15 mg still produces 0.3% to 0.5% better A1c reduction and 3 to 5 kg more weight loss than semaglutide 2.4 mg, but the confidence intervals overlap.

For patients choosing between compounded semaglutide and compounded tirzepatide, the practical takeaway: tirzepatide is the stronger option for both glucose control and weight loss, with modestly higher GI side effects during titration.

What most articles get wrong about "off-label" diabetes use

The common error in patient-facing content: conflating "off-label" with "unapproved" or "experimental."

Off-label prescribing means using an FDA-approved medication for an indication that isn't listed on the FDA-approved label. It's legal, common, and often evidence-based. About 20% of all prescriptions in the United States are off-label (Radley et al., Archives of Internal Medicine, 2006).

Zepbound prescribed for diabetes is off-label but not experimental. The evidence base is the same SURPASS trials that earned Mounjaro its FDA approval. The molecule is FDA-approved. The safety profile is known. The only difference is the indication printed on the box.

The confusion stems from compounded tirzepatide, which is not FDA-approved for any indication. Compounded medications are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They're legal when prescribed by a licensed provider for an individual patient, but they haven't undergone FDA review for safety and efficacy.

The distinction matters:

• Zepbound prescribed off-label for diabetes: FDA-approved drug, non-FDA-approved indication, strong evidence base.
• Compounded tirzepatide prescribed for diabetes or weight loss: Non-FDA-approved drug, no FDA-approved indication, same evidence base as the branded versions but no regulatory review of the specific compounded formulation.

Most articles blur this line and imply that off-label use of Zepbound is somehow riskier than on-label use of Mounjaro. It isn't. The risk profile is identical.

The insulin question: can Zepbound replace basal insulin?

Sometimes, but not always.

SURPASS-3 directly tested this question. Patients with type 2 diabetes on metformin were randomized to either tirzepatide (5, 10, or 15 mg) or insulin degludec (a long-acting basal insulin, titrated to fasting glucose targets). After 40 weeks:

• Tirzepatide 15 mg: A1c reduction of -2.4%, weight loss of 11.7 kg
• Insulin degludec: A1c reduction of -1.4%, weight gain of 2.3 kg

Tirzepatide produced better glucose control and avoided the weight gain that typically accompanies insulin therapy. About 93% of tirzepatide patients reached A1c below 7%, compared to 61% of insulin patients.

The implication: for patients with type 2 diabetes who are candidates for basal insulin, tirzepatide is a reasonable alternative that produces better A1c reduction, better weight outcomes, and lower hypoglycemia risk.

The limitation: tirzepatide doesn't work for everyone. About 10% to 15% of patients don't respond adequately (defined as A1c reduction of less than 0.5% after 6 months at maximum dose). Those patients still need insulin.

SURPASS-5 tested the combination approach: adding tirzepatide to patients already on basal insulin. The result: A1c dropped an additional 2.1%, and patients lost an average of 8.8 kg despite continuing insulin. About half were able to reduce their insulin dose.

The decision framework:

• If A1c is 7.5% to 9.0% and the patient isn't on insulin yet: try tirzepatide first. It's more likely to reach target without the weight gain and hypoglycemia risk of insulin.
• If A1c is above 9.5% or the patient has symptoms of hyperglycemia (polyuria, polydipsia, weight loss): start insulin immediately to get glucose under control quickly, then consider adding tirzepatide later.
• If the patient is already on basal insulin and A1c is still above 7.5%: add tirzepatide rather than escalating to basal-bolus insulin (multiple daily injections). The combination works and avoids the complexity of mealtime insulin.

Tirzepatide doesn't replace insulin in type 1 diabetes or in late-stage type 2 diabetes where beta-cell function is exhausted. It's a substitute or adjunct for patients who still have meaningful endogenous insulin production.

Hypoglycemia risk: when blood sugar drops too low

One of tirzepatide's advantages over insulin and sulfonylureas is the low hypoglycemia risk. The GLP-1 mechanism is glucose-dependent: insulin secretion increases only when blood glucose is elevated. When glucose is normal or low, the signal stops.

In the SURPASS trials, severe hypoglycemia (blood glucose below 54 mg/dL requiring assistance) occurred in:

• 0.6% of tirzepatide patients not on insulin or sulfonylureas
• 0.1% of placebo patients

The rate is barely above placebo. For comparison, basal insulin causes severe hypoglycemia in 2% to 5% of patients per year.

The risk increases when tirzepatide is combined with insulin or sulfonylureas. In SURPASS-5 (tirzepatide added to basal insulin), severe hypoglycemia occurred in 1.7% of patients. Still lower than insulin alone, but not negligible.

The practical protocol when starting tirzepatide in a patient on insulin or sulfonylureas:

1. Reduce the insulin dose by 20% to 30% when starting tirzepatide. Monitor fasting glucose daily for the first 2 weeks.
2. Reduce or stop sulfonylureas (glipizide, glyburide, glimepiride). The combination of sulfonylurea plus GLP-1 agonist creates overlapping insulin-stimulation pathways and increases hypoglycemia risk.
3. Monitor for symptoms: shakiness, sweating, confusion, rapid heartbeat. If blood glucose drops below 70 mg/dL, treat with 15 grams of fast-acting carbohydrate (glucose tablets, juice, regular soda).
4. Recheck glucose after 15 minutes. If still below 70 mg/dL, repeat the 15-gram carbohydrate dose.

Most hypoglycemia events on tirzepatide occur during the first 4 to 8 weeks when the body is adapting to the medication and providers are still titrating background medications. After stabilization, the risk drops close to baseline.

Patients on metformin, SGLT2 inhibitors, or DPP-4 inhibitors can start tirzepatide without dose adjustments. Those drug classes don't cause hypoglycemia on their own and don't meaningfully increase risk when combined with tirzepatide.

The decision framework: Mounjaro vs Zepbound for patients with both conditions

If you have both obesity and type 2 diabetes, which version should you take?

Choose Mounjaro if:

• Your insurance covers Mounjaro with reasonable copay or prior authorization approval.
• Your A1c is above 8.5% and aggressive glucose control is the immediate priority.
• You're already on basal insulin and need additional diabetes medication.
• Your provider is focused on diabetes management and frames the prescription as diabetes treatment.

Choose Zepbound if:

• Your insurance covers Zepbound but not Mounjaro (some plans have better coverage for obesity medications than diabetes medications).
• Your A1c is between 6.5% and 8.0%, and weight loss is the primary goal.
• You're not on insulin, and your provider is taking a weight-first approach.
• Your provider is focused on obesity management and frames the prescription as weight-loss treatment.

Choose compounded tirzepatide if:

• Neither branded version is covered by insurance, or the copay is prohibitively expensive.
• You're paying out of pocket and want the lower cost of compounded medication.
• Your provider is comfortable prescribing compounded GLP-1 medications and has a relationship with a compounding pharmacy (such as the pharmacies FormBlends works with).

The clinical outcomes are the same across all three options. The difference is cost, insurance coverage, and which diagnostic code your provider uses to justify the prescription.

The one scenario where the choice matters clinically: if you're in a clinical trial or research study. Trials specify branded medications by name, and substituting compounded versions may disqualify you from participation.

FormBlends clinical pattern: what we see in dual-diagnosis patients

FormBlends providers see a consistent pattern in patients who start compounded tirzepatide with both obesity and type 2 diabetes:

Phase 1 (Weeks 1 to 8): Glucose drops faster than weight.

A1c typically falls 0.8% to 1.2% during the first 8 weeks, even though weight loss is only 3 to 5 kg. The early A1c drop comes from improved insulin sensitivity and reduced glucagon secretion, not from weight loss itself. Patients often reduce or stop sulfonylureas during this phase.

Phase 2 (Weeks 8 to 24): Weight loss accelerates, glucose stabilizes.

Weight loss reaches 8 to 12 kg by week 24. A1c continues to drop but more slowly, adding another 0.5% to 0.8% reduction. Patients on metformin often continue it. Patients on basal insulin often reduce doses by 30% to 50%.

Phase 3 (Weeks 24 to 52): Plateau and maintenance.

Weight loss slows. Total weight reduction at 52 weeks averages 12 to 18 kg in our patient population (slightly lower than the SURMOUNT trial averages, likely because real-world adherence is imperfect). A1c stabilizes in the 5.8% to 6.5% range for most patients who started between 7.0% and 8.5%.

The subset who reach remission:

About 30% to 35% of our patients with baseline A1c between 6.5% and 7.5% reach A1c below 5.7% (non-diabetic range) and stop all diabetes medications except tirzepatide. This matches the remission rates seen in bariatric surgery literature for patients who lose 15+ kg.

The subset who don't respond:

About 10% to 12% of patients see A1c reduction of less than 0.5% after 6 months at maximum tolerated dose. These patients typically have longer diabetes duration (more than 10 years), higher baseline A1c (above 9.0%), or markers of low beta-cell reserve (low C-peptide levels). They need insulin or additional oral agents.

The pattern we don't see often: patients who lose substantial weight (more than 15 kg) but whose A1c doesn't improve. When weight drops, glucose almost always follows. The rare exceptions are patients with latent autoimmune diabetes of adults (LADA) or other forms of beta-cell failure misdiagnosed as type 2 diabetes.

FAQ

Does Zepbound lower blood sugar?

Yes. Zepbound (tirzepatide) lowers blood glucose by stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying. Clinical trials show an average A1c reduction of 2.1% to 2.5% in patients with type 2 diabetes, comparable to the diabetes-approved version (Mounjaro).

Is Zepbound approved for diabetes?

No. Zepbound is FDA-approved only for chronic weight management in adults with obesity or overweight with weight-related comorbidities. The same molecule is sold as Mounjaro for type 2 diabetes. Providers prescribe Zepbound off-label for patients with both obesity and diabetes when weight loss is the primary goal.

Can I take Zepbound if I have diabetes?

Yes, if your provider prescribes it. Zepbound is safe and effective for patients with type 2 diabetes. The off-label use is supported by the same clinical trial data that earned Mounjaro its diabetes approval. Insurance coverage may be better for Mounjaro if diabetes is your primary diagnosis.

Which is better for diabetes, Zepbound or Mounjaro?

They're identical. Both contain tirzepatide at the same doses. The only difference is the FDA-approved indication. Mounjaro is labeled for diabetes, Zepbound for weight loss. The clinical outcomes are the same.

How much does Zepbound lower A1c?

Zepbound lowers A1c by an average of 2.1% to 2.5% in patients with type 2 diabetes, based on the SURPASS clinical trials. About 80% to 90% of patients reach A1c below 7%, and 30% to 40% reach the non-diabetic range (below 5.7%) depending on baseline A1c.

Can Zepbound replace insulin?

Sometimes. Tirzepatide produces better A1c reduction than basal insulin in head-to-head trials and avoids the weight gain insulin causes. For patients with A1c between 7.5% and 9.0% who are candidates for starting insulin, tirzepatide is a reasonable alternative. For patients already on insulin, tirzepatide can be added to reduce insulin doses.

Does Zepbound cause low blood sugar?

Rarely. Tirzepatide causes severe hypoglycemia in about 0.6% of patients not taking insulin or sulfonylureas. The risk increases to 1% to 2% when combined with insulin. The GLP-1 mechanism is glucose-dependent, meaning insulin secretion stops when blood sugar is normal or low, which prevents most hypoglycemia.

Is Zepbound better than Ozempic for diabetes?

Yes, based on head-to-head trial data. Tirzepatide (Zepbound/Mounjaro) lowers A1c by 0.5% to 0.6% more than semaglutide (Ozempic) at comparable doses and produces 5 to 6 kg more weight loss. The tradeoff is modestly higher nausea rates during titration.

Can I take Zepbound with metformin?

Yes. Metformin and tirzepatide work through different mechanisms and are commonly prescribed together. There are no drug interactions. Most patients with type 2 diabetes continue metformin when starting Zepbound or Mounjaro.

How long does it take for Zepbound to lower blood sugar?

Fasting glucose typically drops within 1 to 2 weeks of starting Zepbound. A1c (which reflects average glucose over 2 to 3 months) shows measurable improvement by 8 to 12 weeks. Maximum A1c reduction occurs at 24 to 40 weeks after reaching maintenance dose.

Does Zepbound work for type 1 diabetes?

No. Zepbound is not approved or recommended for type 1 diabetes. Tirzepatide works by stimulating the pancreas to produce insulin, which requires functioning beta cells. Type 1 diabetes patients have little to no endogenous insulin production and require exogenous insulin.

Can Zepbound cause diabetes remission?

Yes, in a subset of patients. About 30% to 40% of patients with baseline A1c between 6.5% and 7.5% who lose 15 kg or more reach A1c below 5.7% (non-diabetic range) and can stop all diabetes medications except tirzepatide. Remission durability depends on maintaining weight loss.

What happens to blood sugar when you stop Zepbound?

Blood glucose typically rises within 2 to 4 weeks of stopping Zepbound. A1c returns toward baseline over 2 to 3 months. Weight regain is common, which further worsens glucose control. Most patients need to resume diabetes medications if they discontinue tirzepatide.

Does compounded tirzepatide work as well as Zepbound for diabetes?

Compounded tirzepatide contains the same active ingredient and works through the same mechanism. The expected A1c reduction and weight loss are comparable. However, compounded medications aren't FDA-approved and haven't undergone the same quality control testing as branded products. Variability between compounding pharmacies may exist.

Can I take Zepbound if I have prediabetes?

Yes, though it's off-label. Tirzepatide prevents progression from prediabetes to diabetes and often reverses prediabetes to normal glucose tolerance. The SURMOUNT-1 trial included patients with prediabetes, and 95% maintained non-diabetic A1c levels at 72 weeks. Insurance is less likely to cover Zepbound for prediabetes alone.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
6. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
7. Lean MEJ et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018.
8. Urva S et al. Comparative effectiveness of tirzepatide and semaglutide for weight loss: A network meta-analysis. Diabetes Obesity and Metabolism. 2022.
9. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
11. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
14. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Victoza and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.